EUVIMEDEUVIMED entdecken
Crossref

Healthcare utilization in cancer patients treated with immune checkpoint inhibitors: a population-based study of all patients and 1-year survivors

Chia-Lu Hsu, Li-Fan Hsu, Sheng-Yin To, Cho-Hao Lee, Yuan-Liang Wen, Hui-Wen Yang, I-Wen Chen, Li-Ting Kao

Supportive Care in Cancer · 2025

DOI: 10.1007/s00520-025-10127-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Chia-Lu Hsu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, National Defense Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors, Patient Acceptance of Health Care, Cancer Survivors. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Tri-Service General Hospital, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but carry significant costs, posing challenges for patients and healthcare systems. This study aimed to evaluate healthcare utilization using real-world data among cancer patients treated with ICIs, monoclonal antibodies (mAbs), protein kinase inhibitors (PKIs), and chemotherapy (Chemo). METHODS: This study utilized data from the Taiwan Cancer Registry and National Health Insurance Database between January 2019 and December 2020, including 133,786 participants diagnosed with stage III, stage IV, or metastatic cancer. Participants were categorized based on the antineoplastic medications. The outcome variables for healthcare service utilization included the number of outpatient visits, outpatient costs, inpatient days, inpatient costs, and total healthcare costs. RESULTS: This study included 2722 ICI users, 22,499 mAb users, 30,067 PKI users, and 78,498 Chemo users. ICI users demonstrated significantly higher overall healthcare utilization compared to the other groups (p < 0.001). Additionally, both cancer- and noncancer-related costs were elevated among ICI users, primarily driven by the management of respiratory, endocrine, and urological disorders. Notably, ICI users had lower inpatient healthcare service utilization than mAb users in the 1-year survivor population (p < 0.001). CONCLUSION: These findings suggest that although ICI use leads to increased overall healthcare utilization, it is associated with a reduction in inpatient healthcare services. This underscores the need for physicians and policymakers to carefully assess the economic implications of ICIs and develop comprehensive strategies to optimize healthcare resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmune Checkpoint InhibitorsPatient Acceptance of Health CareCancer SurvivorsHumansMaleFemaleMiddle AgedAgedTaiwanAdultProtein Kinase InhibitorsRegistriesHealth Care CostsAntibodies, MonoclonalAged, 80 and over

Stichwörter der Autor:innen

Cancer patientsFinancial burdenHealthcare utilizationImmune checkpoint inhibitors

Substanzen

Immune Checkpoint InhibitorsProtein Kinase InhibitorsAntibodies, Monoclonal

Autor:innen und Institutionen

  • School of Pharmacy, College of Pharmacy, National Defense Medical University, Taipei, Taiwan.
  • Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
  • School of Pharmacy, College of Pharmacy, National Defense Medical University, Taipei, Taiwan. ein060113@gmail.com.
  • Graduate Institute of Life Sciences, College of Biomedical Sciences, National Defense Medical University, Taipei, Taiwan. ein060113@gmail.com.
  • School of Public Health, College of Public Health, National Defense Medical University, Taipei, Taiwan. ein060113@gmail.com.
  • Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.

Förderung

  • Tri-Service General Hospital
  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Hsu, C. L., Hsu, L. F., To, S. Y., Lee, C. H., Wen, Y. L., Yang, H. W., Chen, I. W., & Kao, L. T. (2025). Healthcare utilization in cancer patients treated with immune checkpoint inhibitors: a population-based study of all patients and 1-year survivors. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-10127-2

Vancouver

Hsu CL, Hsu LF, To SY, Lee CH, Wen YL, Yang HW, et al. Healthcare utilization in cancer patients treated with immune checkpoint inhibitors: a population-based study of all patients and 1-year survivors. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-10127-2

BibTeX
@article{Hsu2025,
  author = {Hsu, Chia-Lu and Hsu, Li-Fan and To, Sheng-Yin and Lee, Cho-Hao and Wen, Yuan-Liang and Yang, Hui-Wen and Chen, I-Wen and Kao, Li-Ting},
  title = {Healthcare utilization in cancer patients treated with immune checkpoint inhibitors: a population-based study of all patients and 1-year survivors},
  journal = {Supportive Care in Cancer},
  year = {2025},
  doi = {10.1007/s00520-025-10127-2}
}
Kostenlos starten →